A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer. READ MORE
A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer.
A panel at the SGO 2018 Annual Meeting on Women’s Cancer convened to achieve consensus on PARP inhibitor use for the treatment and maintenance of ovarian cancer in the context of current standards.
Participation in clinical trials may help overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a presentation at the SGO 2018 Annual Meeting on Women’s Cancer.
Health care providers and patients have identified a need for further resources to support survivorship care in gynecologic oncology, according to a presentation given at the 2018 ASCO Cancer Survivorship Symposium.
Research in Review
New research questions the value of risk-reducing mastectomy within five years of ovarian cancer diagnosis in patients with BRCA mutations.
Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options.
Researchers used Surveillance, Epidemiology, and End Results registry data to review the costs associated with treatment plans consistent with NCCN guidelines.
The National Comprehensive Cancer Network has updated their guidelines for the treatment of ovarian cancer, including therapy for stage II-IV disease and persistent disease.
The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.
From March 24-27, the Society of Gynecological Oncology hosted its Annual Meeting on Women's Cancer in New Orleans, Louisiana. The meeting brought together gynecologic oncologists from all over the world to learn to share the latest research and practice innovations in the treatment of gynecologic malignancies.
Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.
Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.